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Summary We have developed a mouse monoclonal antibody SCIl (IgG2a) against cell surface antigen of
Ewing's sarcoma (ES). 5CI1 specifically reacted with ESs but not with other small round cell tumours in
childhood, i.e. neuroblastomas, primitive neuroectodermal tumours (PNETs), rhabdomyosarcomas and malig-
nant lymphomas. 5CII did not react with any other tumours in children except for hepatoblastomas. No
reactivity has been identified in normal tissues with the exception of fetal hepatocytes. Immunoelectron
microscopically, 5CII reactive antigen was located on cell membrane of ES cells. Biochemically, 5CI1
immunoprecipitated a cell surface protein having molecular weight of 81,000 Da. 5C1 is the first antibody
which can clearly distinguish ES from neurogenic tumours, especially from PNETs which were recently
reported to have common features to ESs regarding chromosal abnormality and proto-oncogene expression
but show evident differentiation into neurogenic direction. The results strongly indicate the usefulness of 5CI1I
not only for diagnostic purpose when no specific marker is available but also for studying the histogenesis of
ES. In addition, no reactivity in normal tissue implies its potential application as a therapeutic reagent when
the management of ES patients is still a great problem in clinical field.
Ewing's sarcoma (ES) belongs morphologically to the group
of small round cell tumours of children because of the ab-
sence of unequivocal features of differentiation. This tumour
arises from bone and soft tissue, and the histogenesis is still
unknown. By electron microscopy, several characteristic
features were reported, but specific features of diagnostic
value have not been found. Although several monoclonal and
polyclonal antibodies were applied to ES, no membrane
antigen or protein were known to be specific for ES, and thus
the immunodiagnosis of this tumour has been uncertain
(Donner et al., 1985; Triche et al., 1986). In this study, we
have established a mouse monoclonal antibody, 5Cl which
specifically reacts with ES. The unique distribution and par-
tial biochemical characterisation of 5CI1 -defined molecule
are reported.
Materials and methods
Development ofmouse monoclonal antibodies
ES cell line RD-ES (obtained from American Type Culture
Collection (ATCC)) cells (5 x 107 cells) were injected into the
intraperitoneal cavity of Balb/cA mice at 2-week intervals
three times. Four days after the last boost, immune
splenocytes were fused with NS-1 mouse myeloma cells.
Supernatants of growing hybridomas were screened on
acetone-fixed frozen sections of CR-EW1 tumour, and ES
line heterotransplanted in the nude mice by the indirect
immunoperoxidase method described below. Hybridomas
secreting antibodies of interest were cloned twice by limiting
dilution. Immunoglobulin (Ig) subclass monoclonal
antibodies were determined by immunodiffusion by rabbit
anti-mouse Ig subclass antisera (BIO RAD Laboratories).
Source of tumours
Surgically resected human tumours, tumours maintained in a
nude mice heterotransplantation system and human cell lines
maintained in culture medium were used in this study (Table
I). Seventeen osseous and extraosseous ES tumours and cell
lines were examined in this study. The transplanted tumour
CR-EW2 was derived from case 3. ES cell line NCR-EW1
was derived from CR-EW1, NCR-EW2 from case 2, NCR-
EW3 from case 3 and NCR-EW4 from case 5. SCCH-196
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Table I Ewing's sarcomas examined in this study
Case Age (years)/sex Origin O/EO0
Surgical speciments
I 7/F Mediastinum EO
2 13/M Pelvis EO
3 10/M Chest wall EO
4 34/M Chest wall EO
5 14/F Mediastinum EO
6 9/M R-femor O
7 14/F Hip EO
Cell lines
NCR-EWI 10/M Neck EO
NCR-EW2 13/M Pelvis EO
NCR-EW3 1O/M Chest wall EO
NCR-EW4 14/F Chest wall EO
Transplanted tumours
CR-EWI 10/M Neck EO
CR-EW2 10/M Chest wall EO
ao, osseous; EO, extraosseous.
(Homma et al., 1989) line was kindly provided by Y. Kaneko
(Laboratory Medicine, Saitama Cancer Centre Hospital,
Saitama) and W-ES line by Y. Fujii (Department of Paediat-
rics, Hamamatsu University, School of Medicine, Shizuoka;
Fujii et al., 1989). Both SCCH-196 and W-ES lines have been
shown to have chromosomal translocation with t(I 1; 22).
RD-ES and SK-ES1 (Bloom, 1972) were both obtained from
ATCC. Three cases of primitive neuroectodermal tumour
(PNET)s including one cell line (NCR-PN1) established from
a 2-month-old girl with sciatic nerve tumour in our own
laboratory, were used in this study. In contrast to ES, these
three PNETs revealed ultrastructural and immunohis-
tochemical findings of neurogenic tumours (unpublished
data). Briefly, these tumours were shown to have occasional
neurosecretory granules and microtubules in the cytoplasmic
processes, and they were all positive for anti-neurofilament
antibody (200 kDa; Labsystem, Helsinki, Finland) and anti-
neuron specific enolase antisera (Dakopatts, California).
These tumour tissues were immediately frozen in OCT-
compound (Tissue Tek Division, Miles Scientific
Laboratories Inc.) and stored at - 80°C until use, or fixed in
20% formaldehyde and embedded in paraffin.
Preparation ofnormal andfetal tissues
Normal tissues were obtained from surgery and autopsy.
Normal fetal tissues of 6-12 weeks gestational age which
were obtained at the time of necropsy after spontaneous and
legal abortion were frozen and stored as described above.
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Immunostaining oftissues
Indirect immunoperoxidase staining was performed on
acetone-fixed or 4% paraformaldehyde-fixed frozen sections.
Slides were incubated with monoclonal antibodies (50 l of
culture supernatant) for 30 min at room temperature in a
humidified chamber. After rinsing in O.O1M phosphate
buffered saline (PBS), horseradish peroxidase conjugated rab-
bit IgG anti-mouse whole Igs (Dakopatts, Glostrup, Den-
mark) were similarly applied on slides for 30 min at room
temperature. The slides were then washed in PBS and reacted
with diaminobenzidine (2 mg ml-', in 0.5 M Tris-CHI,
pH 7.4, and 0.005% H202). The sections were counterstained
with methyl green and were observed under light microscopy.
When sections of tissues obtained from nude mice were used,
endogenous mouse Ig, which would react with the second
reagent, were blocked by treating the slides with a Fab
fragment of rabbit anti-mouse Ig before application of the
first monoclonal antibodies. In some experiments, culture
cells were stained by an immunoperoxidase method in the
same manner after they were attached to slides by centrifuga-
tion using Cytospin (Shandon Southern Products Limited,
Cheshire, England).
Flow cytometrical analysis
Two million cells were suspended in 100 yl of PBS and
incubated with monoclonal antibodies (100 pl of culture
supernatant) for 30 min at 4°C. After washing in PBS by
centrifugation, they were incubated with fluorescein-
conjugated rabbit IgG to mouse Igs (Dakopatts, Glostrup,
Denmark). After washing in PBS, they were resuspended in
PBS and 10,000 (cells were analysed by flow cytometer
(Epics-Profile, Coutler Corporation, Florida, USA)).
Immunoelectron microscopy
RD-ES cells were fixed in 0.05 M phosphate-buffered, 4%
paraformaldehyde and attached to slides by Cytospin. They
were examined by immunoelectron microscopy according to
the method previously described (Akatsuka et al., 1979; Hata
et al., 1980).
Immunoprecipitation and SDS-PAGE
RD-ES cells were externally labelled with 1251I by lactoperox-
idase. Briefly, 2 x 107 cells were labelled with I mCi of Na
1251 by the lactoperoxidase catalysing method described by
Haustein (1975). After iodination, cells were washed three
times with PBS and the cell membrane was disrupted by
adding I ml of lysing buffer (1% Triton X-100, 0.05 M Tris-
HC1, pH 7.4 containing 0.14 M NaCI, 0.05 M EDTA, 0.01 M
phenylmetyl sulphonyl fluoride, 0.05% sodium azide) for 1 h
at 4°C. After centrifugation, 200 iLl of the labelled cell memb-
rane (equivalent to 106 c.p.m.) were incubated with mono-
clonal antibodies coupled to CNBr-activated Sepharose 4B
(Pharmacia) (I mg antibodies per ml of wet volume) for 3 h
at 4°C. The beads were washed with washing buffer (0.01 M
Tris-HCl, pH 8.0, 0.5 M NaCl, 0.1% Triton X-100, 0.05%
sodium azide), and were extracted with sodium dodesyl
sulphate-poly acrylamide gel electrophoresis (SDS-PAGE)
sample buffer (0.06 M Tris-HC1, 3% SDS, 10% glycerol,
0.04% bromophenol blue, with and without 2-
mercaptoethanol (2-ME)) and boiled for 5 min. The SDS-
PAGE was performed either under reducing condition with
5% 2-ME or non-reducing condition without 2-ME. The gel
was dried and autoradiographed on Kodak XAR-5 X-ray
film.
Results
Establishment ofmouse monoclonal antibodies
Of 406 growing hybridomas, three clones were selected
because they reacted strongly with ES but not, or weakly,
with neuroblasoma (NB) and normal kidney by
immunoperoxidase staining. Two clones (7H6 and 8B1)
reacted with both ES and NB, but also with some com-
ponents of kidney. On the other hand, 5Cll only reacted
with Es but not with NB and kidney. In this study, 5C1 1 was
further investigated. The Ig subclass of 5C1 1 was determined
as IgG2a by immunodiffusion.
Reactivity ofC5J on human tumours
Reactivity of 5Cll with various human tumours was inves-
tigated by immunoperoxidase and the results are listed in
Table II. 5C1 reacted with 16 of 17 ESs regardless of their
origins (osseous or extraosseous). Figure la and b shows the
typical histology of ES. In Figure lb, a rosette-like structure
is clearly seen. As is shown in Figure lc, 5C1 1 reacts with all
tumour cells of ES. One ES line, NCR-EWI, unreactive to
5C11, was derived from the transplanted tumour CR-EW1
which was used at the first screening as positive control.
Although the mechanism is unknown, 5C11 expression
seemed to be lost during in vitro culture in this particular cell
line. The localisation of 5C1 1 antigen on ES cells was further
investigated by immunoelectron microscopy and the antigen
was found to be present on the cell membrane (Figure 2).
5C11 did not react with NBs, PNETs, rhabdomyosarcomas
and lymphomas. Identical results were obtained on cell ines
by immunofluorescence followed by flow cytometrical
analysis. Typical examples are shown in Figure 3. Thus ES
lines RD-ES, SK-ES1, NCR-EW2 (Figure 3a, and c, respec-
tively) were all 5C11 positive, whereas PNET line (NCR-
PN1) (Figure 3d) and NB lines, IMR-32 (Tumilowicz et al.,
1970) (Figure 3e) and GOTO (Sekiguchi et al., 1979 and
Figure 3f) were completely 5Cll negative. 5C1l was inves-
tigated on other human tumours in children and it was found
that 5Cll did not react with any other tumours except for
hepatoblastomas (HB). On HBs 5C1l reacted with all four
cases. The reactivity of 5C1 1 on HB was found on cell
surface. Reactivity of 5C1I was stable on acetone-fixed
frozen section and paraformaldehyde-fixe tissue but was lost
when tissues were processed for formalin-fixation followed by
paraffin-embedding.
Reactivity of5CJI on normal andfetal tissues
A variety of normal and fetal human tissues were studied for
the distribution of 5Ci1-defined antigen. 5C11 did not react
with any normal tissues with the number of samples
indicated (Table III). In fetal tissues, a strong reactivity of
SC 11 was detected in hepatocytes but no reactivity was found
in any other tissues (Table IV). Interestingly, SCi1 did not
react with hepatocytes of new born babies and adults,
indicating the oncofetal nature of 5C11-defined antigen.
Biochemical characterisation ofSCI 1-defined molecule
Biochemical characterisation of 5CII-defined molecule was
carried out using RD-ES line. As is shown in Figure 4, 5C1 1
immunoprecipitated a protein having molecular weight (MW)
Table II Immunoreactivities of 5C 1 on tumours
Tumour tissues tested No. ofpositive/ No. tested
Ewing's sarcoma
EOa 13/14
oa 2/2
unknown 1/1
Neuroblastoma 0/22
PNET 0/3
Rhabdomyosarcoma 0/10
Osteosarcoma 0/3
Wilm's tumour 0/5
Hepatoblastoma 4/4
Malignant lymphoma 0/3
PNET, primitive neuroectodermal tumour. 'EO, extraosseous; 0,
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Figure 1 Histology of ESs (paraffin section) and the reactivity of
5Cl with these tumour (frozen section). a (case 2), b (case 3),
Haematoxylin and Eosin stain ( x 100). b, rosette-like arrange-
ment is clearly seen in case 3. c, 5C I stain ( x 100) on case 3.
5Cl reacts with all tumour cells in case 3. Identical reactivity
was observed in case 2 (data not shown). R, rosette-like arrange-
ment. d, control antibody.
of 81 KD (Figure 4 lanes a and c) under both reducing and
non-reducing conditions, suggesting that 5C1 1 reactive
moleclues do not have a subunit structure linked by a disul-
phide bond. No specific band was identified when class mat-
ched irrelevant antibody was used as control (Figure 4 lanes
b and d).
5Cll reactive antigen on HB was also studied using cell
suspension prepared from heterotransplantable HB, CR-HP3
and it was found that SC I reacted with the protein having a
molecular weight identical to that on ES (data not shown).
Discussion
Among malignant small round cell tumours, ES is considered
as the most primitive due to the absence of unequivocal
morphological characteristics as well as differentiation
capability. Although several hypotheses have been reported,
the histogenesis of ES still remains obscure. Accordingly, the
specific features of diagnostic value of this tumour have not
yet been determined.
Figure 2 Immunoelectron microscopic detection of SCI1-defined
antigen in RD-ES cell. Note the location of SCI I reactive
molecule on the cell membrane ( x 3700). N, nucleus of the
tumour cell.
In an effort to develop a reliable probe useful for charac-
terising ES, we have successfully established a monoclonal
antibody 5Cl1 which specifically reacts with ES. Reactivity
of 5C1 1 was examined with a panel of tumour tissues and it
was found that 5C1 1 only reacted with ES among tumours in
childhood except for HB. In addition, 5C 1I reacted with
both osseous and extraosseous ESs. Identical specificity of
5C11 was also shown on a variety of cell lines in vitro. These
results clearly indicate that 5Cl1 is an extremely useful tool
in diagnostic pathology field for prompt and accurate diag-
nosis. It is of note that 5C11 can distinguish ES from PNET,
the latter of which shows more clear differentiation capability
towards neurogenic tissues as revealed by ultrastructural
features such as the presence of neurosecretory granules and
by the production of tissue specific proteins such as
neurofilaments. On the other hand, cytogenetical analysis has
shown that PNET and some ES have the same chromosomal
abnormalities involving (11; 22) (q24 ; ql2) (Aurius et al.,
1983; Turc-Carel et al., 1983; Whang-Peng et al., 1984). In
addition, common proto-oncogene expression has been
observed in PNET and ES (Mckeon et al., 1988). In fact,
some ES cells which we established could be induced to
differentiate into neural direction by the administration of
cyclic AMP in vitro (unpublished observation). In such a
Table III Immunoreactivity of 5CII on normal tissues
Specimens No. oftested Reactivity
Brain
Spine
Stomach
Intestine
Lung
Liver
Kidney
Adrenal cortex
Adrenal medulla
Sympathetic ganglion
Testis
Muscle
Bone
Bone marrow
Peripheral blood
Thymus
Tonsil
Lymph node
5
5
4
4
4
5
5
6
6
4
4
4
4
8
4
4
4
5
-, negative; + positive.
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Figure 3 Flow cytometrical analysis. Cells were reacted with 5C II (ii) or with control antibody RI-1OB5 (i) and were analysed by
flow cytometer. The x-axis shows the log green fluorescence intensity and the y-axis represents the relative cell number. Note the
clear positive peaks on ES lines, RD-ES (a), SK-ESI (b) and NCR-EW2 (c) with 5ClI. PNET line, NCR-PN1 (d) and NB lines,
IMR-32 (e) and GOTO (f) were completely negative for 5C 1. As a control antibody class matched irrelevant monoclonal
antibody, RI-IOB5 (Matsuura et al., 1984) was used.
Table IV Immunoreactivity of 5C11 on fetal tissues
Specimens No. oftested Reactivity
Brain 2 -
Spine 2
Neural crest 4
Myoblast 4
Cardium 4
Bone and osteoblast 4
Intestine 4
Lung 2
Liver 4 a
Kidney 4
Bone marrow 4
-, negative; + positive. aPositive on hepatocytes.
d-;A
67k-.
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circumstance reactivity of SCII was shown to decrease by
flow cyctometer (unpublished observation, manuscript in
preparation). Therefore, it is of interest to compare 5CII
with monoclonal antibody HBA-71 (Hamilton et al., 1988)
developed recently against PNET. HBA-71 reacts both with
ES and PNET but not with other small round cell tumours
including typical NB, indicating that this antibody defines a
molecule expressed commonly on ES and PNET. From the
results we obtained, however, ES and PNET have different
phenotype which first becomes evident utilising 5Cll. HBA-
71 seems to react with a complex molecule having molecular
weights of 300 kDa, 185 kDa and 90 kDa, whereas 5C11
immunoprecipitates distinct cell surface with a molecular
weight of 81 kDa. By immunoelecton microscopic examina-
tion, 5C11 antigen was confirmed to localise exclusively on
the cell membrane of ES cells.
Distribution of 5Cil reactive antigen on normal tissues
was also studied but no reactivity has yet been identified in
fetal and adult tissues except for fetal hepatocytes at certain
gestational age, since hepatocytes of a new born baby no
longer expressed this molecule. Consistent with this observa-
tion, HBs, the malignant counterpart of fetal liver cells, were
positive for 5Cil, indicating that 5Cll reactive molecule is
an oncofetal antigen in nature. No reactivity on adult tissue,
however, implies a great advantage for further application of
this antibody in vivo for tumour imaging as well as for
therapeutic reagent. Since management of ES is a very
serious problem in the clinical field, new approaches to treat-
ment such as in vivo administration of specific antibody must
now be considered. Although the biological significance of.*.-.*......*.
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Figure 4 SDS-PAGE of 5C1I reactive molecule on RD-ES.
Immunoprecipitation of 5C11 (a, c) and control antibody (RI-
lOB5) (b, d) with cell surface radioiodinated materials from RD-
ES were analysed under both reducing (a, b) and non-reducing (c,
d) condition.
the SC11-reactive molecule has not yet been elucidated, 5C11
has a wide range of application not only for immunodiag-
nosis but also in the management of ES. The in vivo use of
5Cll is now under investigation by using ES tumours xeno-
transplanted in nude mice.
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